Sentence examples for one dose of protocol from inspiring English sources

Safety analysis was performed on the group of patients who received at least one dose of protocol medication.

Each patient after having at least one dose of protocol therapy was evaluable for toxicity.

An interim safety analysis will employ stopping rules after 30% of planned patients have been treated with at least one dose of protocol therapy to ensure the combination does not confer excessive toxicity.

For the analysis set of patients, we used the intent-to-treat (ITT) population, and patients who did not receive even one dose of predetermined protocol chemotherapy were excluded.

Secondarily, an analysis was performed in the per-protocol population, which was defined as all subjects who received at least one dose of study medication, had no major protocol violations and had a study drug compliance of at least 75%.

The Full Analysis Set (FAS) consists of all patients of the randomised population who receive at least one dose of treatment in either group regardless of protocol deviations.

Therefore, groups of mice (n=5) were immunized intramuscularly according to the following protocol: (i) one dose of non-adjuvanted vaccine containing 7 µg of HA; (ii) one dose of vaccine containing 7 µg HA in Freund's adjuvant; (iii) two doses of adjuvanted vaccine containing 7 µg HA and administered 2 weeks apart; and (iv) one dose of adjuvanted vaccine containing 15 µg HA.

Our vaccination protocol consisted of one dose of intramuscular injection of monovalent adjuvanted (MF59C1) H1N1 inactivated influenza vaccine.

One further patient at 390 mg m−2 level treated with only one dose of irinotecan was withdrawn because of a protocol violation.

This population included all randomized participants treated with at least one dose of study insulin and without a major protocol deviation that would interfere with treatment efficacy.

The efficacy evaluable (EE) population included all patients who received at least one dose of the investigational drug, were not major protocol violators, and had at least one on-study tumor assessment, besides baseline, or experienced early progression or toxicity.